Moreover, concerning diabetic neuropathy, Bierhaus et al. [107] showed that the administration of a specifically designed MG scavenger (GERP10, [128]) lowers the plasma levels of MG and MG-H1 and is thereby able to reduce the severity of clinically apparent hyperalgesia. This evidence concerns the gene MGAM and diabetic neuropathy.